Acura Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of deterrents to medication abuse and misuse.[3] As of 2012, the company had several opioid products under development, which would use "Aversion Technology".[4] As of 2014, it was a publicly traded company, listed on NASDAQ under the symbol "ACUR".
History
In 2013, the Company settled Oxecta patent litigation with Impax Laboratories (IPXL) and Par Pharmaceutical.[5]
License agreements
The company has an agreement to license, develop and commercialize opioid analgesic products with King Pharmaceuticals.[6]
Product adoptions
In 2013, multiple retailers – including Kroger and Fruth Pharmacy – stocked Acura's product Nexafed.[7][8]
External links
References
- ACURA PHARMACEUTICALS, INC EDGAR Online, Acura Pharmaceuticals, March 31, 1997, retrieved February 15, 2014^
- Acura Pharmaceuticals Financial Statements United States Securities and Exchange Commission^
- Acura Pharmaceuticals Announces Second Quarter 2020 Financial Results AP NEWS, 2020-08-14, retrieved 2021-07-22^
- Acura Pharmaceuticals, Inc. Google Finance, retrieved February 15, 2014^
- Acura Pharmaceuticals Inc Announces Settlement of Oxecta Patent Litigation With Par Pharmaceutical and Impax Laboratories Inc Reuters, Reuters, October 9, 2013^
- ACURA PHARMACEUTICALS INC (ACUR) Company Profile & Facts - Yahoo Finance^
- Rebecca Olsavsky. Kroger stocks meth-resistant drug Herald-Star, February 4, 2014, retrieved February 15, 2014^
- New Pseudoephedrine Drug Could Hop Back Over the Counter PharmExec, 11 December 2012, retrieved 2021-07-22^